Emergence Therapeutics AG Announces Key Hirings to Senior Management Team

Substantial experience in cancer targets, ADC technology as well as corporate finances and law

Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr. Florence Lhospice joins Emergence from Innate Pharma where she has been Senior Director, head of ADC development, head of CMC and Program Manager. Carsten Dehning is the former CEO and CFO of Biovertis, CFO of Albireo Pharma and DeveloGen, and Chairman and CEO of Aspireo Pharmaceuticals.

The management team further comprises co-founder and Chief Executive Officer, Dr. Jack Elands, founder of Talix Therapeutics, CEO of BliNK Biomedical and former CEO of Amakem and Vitec; Chief Scientific Officer and co-founder, Dr. Xavier Preville, former CSO at Talix Therapeutics, director of preclinical development at Transgene and BT Pharma (Genticel).

Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, commented: “Dr. Florence Lhospice has significant experience in the biotech industry and brings major CMC and ADC expertise to the company. As Chief Development officer Florence will be responsible for formal preclinical and CMC related development. Carsten Dehning enriches the management team with his substantial expertise in corporate management, finances and legal matters. With Florence and Carsten on board we now have a great team of biotech experts with many years of experience. And with a growing network of further experts around us we are fully equipped to deliver on our goals.”

Latest News

25/11/2020

Emergence Therapeutics Announces Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany – Marseille, France, 25 November 2020: Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of...

View Article >
10/03/2020

Emergence Therapeutics AG Announces Establishment of Scientific Advisory Board

Key Opinion Leaders bring many years of ADC development expertise to the company Duisburg, Germany - Marseille, France, 10 March 2020: Emergence Therapeutics today announced that is has established its Scientific Advisory Board (SAB) to support the company in its goal to develop novel and innovative antibody-drug-conjugates (ADCs).

View Article >
22/01/2020

Emergence Therapeutics AG Announces Key Hirings to Senior Management Team

Substantial experience in cancer targets, ADC technology as well as corporate finances and law Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr....

View Article >